title: Immunohistochemical expression of Annexin A2 and S100A proteins in patients with bulky stage IB-IIA cervical cancer treated with neoadjuvant chemotherapy.
abstract: OBJECTIVE
  Abnormal expression of Annexin A2 and S100A proteins has been reported to induce sensitivity/resistance to chemotherapy in a variety of cancers. The aim of this study was to evaluate the significance of Annexin A2 and S100A protein expression to predict response to neoadjuvant chemotherapy and prognostic significance of these protein expressions in bulky stage IB-IIA cervical cancer patients.
  
  
  METHODS
  Paired tumor samples (pre- and post-chemotherapy) were obtained from 68 patients who were treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy at our hospital from 2006 to 2011. The expression of Annexin A2 and S100A proteins was analyzed by immunohistochemistry.
  
  
  RESULTS
  Thirty-six patients were identified as chemotherapy-response and 32 were non-response. (a). Protein expression in tumor cells: (1). Exposure of tumor cells to chemotherapy results in a change of Annexin A2 and S100A expression (P<0.05). (2). Annexin A2, S100A8 and S100A9 protein expression correlates with tumor response to chemotherapy (P<0.05). (b). Protein expression in stromal cells: (1). Expression of Annexin A2, S100A8 and S100A9 was increased, but S100A2 and S100A4 was decreased after exposure to chemotherapy (P<0.05). (2). Only S100A4 expression was associated with response to chemotherapy (P<0.05). Multivariate analysis revealed that tumor size (P=0.022), differentiation (P=0.000), Annexin A2 expression in stromal cells (P=0.009), and S100A8 expression in tumor cells (P=0.008) were independent prognostic factors for progression-free survival of cervical cancer patients.
  
  
  CONCLUSIONS
  Expression of some of the measured proteins in tumor and stromal cells correlates with chemotherapy exposure, response to therapy, and progression-free survival.
authors.affiliation: Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical College, Wenzhou 325027, China.
authors.forename: LanYing
authors.initials: L
authors.lastname: Jin
authors.forename: Qi
authors.initials: Q
authors.lastname: Shen
authors.forename: Shengdi
authors.initials: S
authors.lastname: Ding
authors.forename: Wenxiao
authors.initials: W
authors.lastname: Jiang
authors.forename: Lingling
authors.initials: L
authors.lastname: Jiang
authors.forename: Xueqiong
authors.initials: X
authors.lastname: Zhu
mesh_terms: D000328:Adult; D017306:Annexin A2 / Q000096:biosynthesis* / Q000235:genetics; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D007044:Hysterectomy; D007150:Immunohistochemistry / Q000379:methods; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011379:Prognosis; D009418:S100 Proteins / Q000096:biosynthesis* / Q000235:genetics; D017154:Stromal Cells / Q000378:metabolism / Q000473:pathology; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology / Q000601:surgery
chemical_list: D017306:Annexin A2; D009418:S100 Proteins